A Phase 3 Open-Label Randomized Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma
Brief description of study
The purpose of this study involves research and is being conducted to determine the safety and efficacy of the investigational agent, rAd-IFN, when given with Celecoxib and Gemcitabine. The sponsor believes that rAd-IFN in combination with Celecoxib and Gemcitabine may help inhibit your tumor growth.
Clinical Study Identifier: s17-01785
ClinicalTrials.gov Identifier: NCT03710876
Principal Investigator:
Daniel H. Sterman.
Other Investigators:
Vamsidhar Velcheti,
Harvey I Pass,
Samaan Rafeq,
Elaine Shum,
Gaetane C. Michaud,
Jonathan Gross,
Abraham Chachoua,
Joshua K Sabari,
Jamie L. Bessich,
Anissa Lajean Walker,
William H. Moore,
David Mendoza,
Bedros Taslakian,
Natalia Cherkassky,
Melissa L Martinez,
Virginia M Ferreira.
If you are registered as a volunteer, please login to the dashboard to send referrals.